Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

ArcticZymes reports strong Q2 growth and significantly higher profitability

ArcticZymes reported Q2 2026 revenue of NOK 33.9m (+17% y/y) and EBITDA of NOK 7.4m, a 90% increase. Gross margin remained around 95% and the EBITDA margin rose to 23%, supported by broader demand in biomanufacturing and molecular tools (segment revenue +84%). The company closed the quarter with NOK 269m in cash, sees continued operational leverage and reports several programs moving into delivery or commercialization phases. » More on de.investing.com
ArcticZymes Technologies ASA posts Q2 results — shares jump after strong biomanufacturing performance

ArcticZymes Technologies ASA reports Q2 2025 revenue of just under NOK 29 million (+1% y/y) and improved EBITDA of NOK 3.9 million, driven by a 50% revenue increase in biomanufacturing. The share price surged 32.29% following the announcement, and the company signals further growth in biomanufacturing, is exploring CDMO partnerships and potential acquisitions. Challenges remain, including a 40% decline in the molecular tools segment and dependencies on key customers. » More on de.investing.com

Financials

In the last quarter, ArcticZymes had revenue of €2.82M and net profit of €464.02K

(EUR)	June 2026	YoY
Revenue	2.82M	25.17%
Gross profit	1.05M	50.24%
Net profit	464.02K	67.97%
EBITDA	656.7K	100.31%

Fundamentals

Metric	Value
Market capitalization	€99.72M
Number of shares	51.07M
52-week high/low	€2.93 - €1.76
Dividends	No
Beta	0.57
P/E ratio	67.35
PEG ratio	0.07
P/B ratio	2.99
P/S ratio	8.21

Company profile

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, In vitro diagnostics, and biomanufacturing. It offers salt active nuclease for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; shrimp alkaline phosphatase and derived kits for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays; double-strand specific DNases and derived kits for the removal of double stranded DNA; polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining DNA /RNA fragments. It operates in Norway, Germany, Lithuania, Italy, other countries in Europe, the United States, and internationally. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was incorporated in 1990 and is headquartered in Tromsø, Norway.